We were delighted to meet with Messoud Ashina (University of Copenhagen, Copenhagen, Denmark) to discuss the long term safety and tolerability profile of atogepant, and its place as a preventative option for migraine.
The abstract entitled: ‘Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
1. What has the study taught us about the long term safety and tolerability profile of atogepant? (0:14)
2. What place is atogepant likely to play in the preventative treatment paradigm for migraine? (3:01)
Disclosures: Messoud Ashina has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and Teva; is the principal investigator for AbbVie/Allergan, Amgen, Eli Lilly and Lundbeck in ongoing clinical trials; has received Research grants form Lundbeck Foundation, Novo Nordisk Foundation, and Novartis; has no ownership interest and does not own stocks of any pharmaceutical company. Messoud Ashina is also an Associate Editor of Cephalalgia and associate editor of the Journal of Headache and Pain, and is the President of the International Headache Society.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Stephanie Nahas, AHS 2021: HALO Long Term Study Results
We had the great pleasure of meeting with Stephanie Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss the HALO long term extension study investigating long term efficacy and tolerability of fremanezumab in patients with episodic and chronic migraine. The abstract ‘Clinically Meaningful Responses to Fremanezumab Treatment in Episodic and Chronic Migraine […]
Stephanie Nahas, AHS 2021: Results from the CaMEO Study
We had the great pleasure of meeting with Stephanie Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss the CaMEO results, a web-based survey to characterize self-reported use of preventive medications for migraine and treatment gaps. The abstract ‘Characterizing preventive treatment gaps in migraine: Results from the CaMEO study’ & ‘Optimal acute […]
Robert Shapiro, AHS 2021: COVID-19 Incidence and Mortality Among Individuals with Migraine
touchNEUROLOGY met with Robert Shapiro (Larner College of Medicine at the University of Vermont, Burlington, VT, USA) to discuss the impact of COVID-19 on individuals with migraine. The abstract ‘Migraine Is Associated With Higher Incidence of COVID-19, and Higher Frequency of COVID-19 Symptoms, but Lower COVID-19-Associated Health Care Resource Utilization Rates’ was presented at the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!